Gathering the record
Relay is organizing the evidence and source boundaries.
Unvalidated marketed peptide name
A commercial name used for unclear or inconsistent substances, often discussed for brain-related effects.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
No direct administered-human Adalank study was located.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
The current record is not large enough to characterize uncommon or long-term harms reliably.
No direct evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNo FDA approval, recognized nonproprietary identity, registered human trial, or peer-reviewed direct evidence located under the name Adalank. What exact molecule the name denotes and whether any claimed sequence has been manufactured, characterized, or studied in humans.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
The marketed name does not establish a reproducibly defined human-study product. Selank evidence cannot supply Adalank dosing.
What would fill this gap: Verified chemical identity plus a matching primary human regimen.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
No single standardized Adalank identity or direct administered-human study was located. Selank research cannot be reassigned to an unverified product name.
Population: No directly studied human population was verified for this identity.
Design: No direct peer-reviewed or registered study located
No direct primary administration source was verified for this exact identity.
Mechanisms
Some commercial pages describe a modified Selank sequence; others use broader nootropic language. Evidence for Selank cannot be transferred to an unverified analog without analytical identity and direct studies.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Identity-ambiguous; no direct evidence.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
What exact molecule the name denotes and whether any claimed sequence has been manufactured, characterized, or studied in humans.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Adalank direct evidence: amounts and schedules describe this route record only.
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Conflicting identity claims prevent reliable source matching and product comparison. The section remains incomplete because the molecule, reference standard, exposure, effects, and safety are not established. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Background human peptide research
Population not stated.
Endpoints were not fully described in the current record.
Human Selank research exists, but it does not study or validate Adalank.
Study administration: Not stated in the current record.
Limitations: Different or unverified identity; no evidence transfer is justified.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 26199585